Keywords
Autoimmune hemolytic anemia
Bortezomib
Refractory treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the efficacy of Bortezomib in the treatment of refractory Autoimmune Hemolytic Anemia in a patient with Systemic Lupus Erythematosus and to explore and document the clinical trajectory of a patient with SLE who developed refractory AIHA. This includes documenting the clinical presentation and progression of AIHA in the patient; evaluating the efficacy of the different treatments used; and analyzing the patient’s response to Bortezomib treatment. Case detail: This is a case study of a 26-year-old patient with SLE who developed refractory AIHA. Data were collected from medical records and clinical follow-up. The patient was diagnosed with SLE in 2008 and developed refractory AIHA. After multiple lines of treatment, the patient had a significant response to Bortezomib, although she experienced many side effects. Final considerations: The case study highlights the need for more research to explore the potential of Bortezomib and other therapeutic alternatives in the treatment of refractory AIHA in patients with SLE. The patient had a significant response to Bortezomib, but also experienced many side effects.
References
ATZORI L, et al. Facial cellulitis associated with complicating ophthalmic herpes zoster. Dermatology Online Journal, 2044; (1): 2-16.
BORBA EF, et al. Consenso de lúpus eritematoso sistêmico. Revista Brasileira de Reumatologia, 2018; 58(6): 621-634.
CARVALHO C. Congestão Pulmonar: Fisiopatologia e Tratamento. ABC da Enfermagem, 2023; (3): 7-32.
FERNÁNDEZ AC, et al. Bortezomib en mieloma múltiple en recidiva o refractario: resultados en una cohorte de 39 pacientes. Revista Clínica Española, 2008; 208(1): 13-19.
GOUDOURIS ES, et al. II Consenso Brasileiro sobre o uso de imunoglobulina humana em pacientes com imunodeficiências primárias. 2022; (1): 1-101.
HILL A, HILL QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program, 2018; 2018(1): 382–389.
JOHNSON E, et al. Bortezomib for the Management of Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: A Scoping Review. Blood, 2021.
KARAGEORGAS T, et al. Bortezomib: um inibidor de proteassoma para o tratamento de doenças autoimunes. Inflammopharmacology, 2021; 29: 1291–1306.
KHALESI N, et al. Bortezomib: um inibidor de proteassoma para o tratamento de doenças autoimunes. Inflammopharmacology, 2021; 29: 1291–1306.
KUTER DJ. Warm autoimmune hemolytic anemia and the best treatment strategies. Hematology, 2020; 2020(1): 625-633.
MCGLOTHLIN J, et al. Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia. Blood, 2022.
MORAND EF, et al. Advances in the management of systemic lupus erythematosus. The Lancet, 2022; 400(10316): 2145-2158.
PATEL BK. Insuficiência respiratória. MSD Manual, 2022; (5): 1-22.
RIFKIN RM, et al. In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood Cancer Journal, 2023; 13:147.
ROCHA FL, HARA C, BARBOSA IG. Tratamento medicamentoso da depressão maior refratária. Revista Eletrônica Acervo Saúde, 2022.
SALIMI A, et al. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer, 2022; 22: 735.
SCHUR PH, BERLINER N. Hematologic manifestations of systemic lupus erythematosus. Blood, 2022; 140(1): 23-34.
SULIMIERA MICHALAK S, et al. Autoimmune hemolytic anemia: current knowledge and perspectives. Immunity & Ageing, 2020; 17: 38.
TSANG-A-SJOE MWP, BULTINK IEM. New developments in systemic lupus erythematosus. Rheumatology, 2021; 60(6): vi21–vi28.